您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > SB-200646
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
SB-200646
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
SB-200646图片
CAS NO:143797-63-1
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品介绍
SB-200646 是第一个对5-HT2B/2C的选择性超过 5-HT2A的拮抗剂,5-HT2B5-HT2C和 5-HT2ApKi值分别为 7.5、6.9 和 5.2。SB-200646 具有口服活性,在体内具有电生理和抗焦虑特性。
生物活性

SB-200646 is the first selective5-HT2B/2Cover 5-HT2Areceptor antagonist withpKivalues of 7.5, 6.9 and 5.2 for5-HT2B,5-HT2Cand 5-HT2A, respectively. SB-200646 is orally active and has electrophysiological and anxiolytic properties in vivo[1][2].

IC50& Target[1][2]

5-HT2BReceptor

7.5 (pKi)

5-HT2CReceptor

6.9 (pKi)

5-HT2AReceptor

5.2 (pKi)

体外研究
(In Vitro)

SB-200646A (4 μM) abolishes the ethanol-induced increase in miniature inhibitory postsynaptic current (mIPSC) frequency and had no effect on basal mIPSC frequency[1].

体内研究
(In Vivo)

SB-200646A (20 mg/kg; intravenous injection; daily; for 21 days; male albino Sprague-Dawley rats) treatment significantly decreases the number of spontaneously active ventral tegmental area (VTA) dopaminergic neurons[1].
The i.v. administration of 4-16 mg/kg of SB-200646A significantly increases the firing rate and % events as bursts in spontaneously active VTA dopaminergic neurons and significantly increases the % events as burst in substantia nigra pars compacta (SNC) dopaminergic neurons[1].

Animal Model:Male albino Sprague-Dawley rats (200-225 g at the beginning of treatment and 300-350 g at the time of the experiment)[1]
Dosage:20 mg/kg
Administration:Intravenous injection; daily; for 21 days
Result:Significantly decreased the number of spontaneously active ventral tegmental area (VTA) dopaminergic neurons.
分子量

266.30

Formula

C15H14N4O

CAS 号

143797-63-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.